"Antibodies, Blocking" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies that inhibit the reaction between ANTIGEN and other antibodies or sensitized T-LYMPHOCYTES (e.g., antibodies of the IMMUNOGLOBULIN G class that compete with IGE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumors and prevent destruction of tumor cells by CYTOTOXIC T-LYMPHOCYTES have also been called enhancing antibodies. (Rosen et al., Dictionary of Immunology, 1989)
| Descriptor ID |
D019138
|
| MeSH Number(s) |
D12.776.124.486.485.114.143 D12.776.124.790.651.114.143 D12.776.377.715.548.114.143
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Blocking".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Blocking".
This graph shows the total number of publications written about "Antibodies, Blocking" by people in this website by year, and whether "Antibodies, Blocking" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Blocking" by people in Profiles.
-
Cianci R, Lolli S, Pagliari D, Gambassi G, Frosali S, Marmo R, Melioli G, Orlando A, Newton EE, Serone E, Landolfi R, Pandolfi F, Frezza D. The involvement of IgH enhancer HS1.2 in the pathogenesis of Crohn's disease: how the immune system can influence a multifactorial disease. Eur Rev Med Pharmacol Sci. 2016 09; 20(17):3618-27.
-
Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013 Aug 26; 210(9):1695-710.
-
Terai M, Eto M, Young GD, Berd D, Mastrangelo MJ, Tamura Y, Harigaya K, Sato T. Interleukin 6 mediates production of interleukin 10 in metastatic melanoma. Cancer Immunol Immunother. 2012 Feb; 61(2):145-155.
-
Mueller M, Spangenberg HC, Kersting N, Altay T, Blum HE, Klenerman P, Thimme R, Semmo N. Virus-specific CD4+ T cell responses in chronic HCV infection in blood and liver identified by antigen-specific upregulation of CD154. J Hepatol. 2010 Jun; 52(6):800-11.
-
San Antonio JD, Zoeller JJ, Habursky K, Turner K, Pimtong W, Burrows M, Choi S, Basra S, Bennett JS, DeGrado WF, Iozzo RV. A key role for the integrin alpha2beta1 in experimental and developmental angiogenesis. Am J Pathol. 2009 Sep; 175(3):1338-47.
-
Baudino L, Nimmerjahn F, Azeredo da Silveira S, Martinez-Soria E, Saito T, Carroll M, Ravetch JV, Verbeek JS, Izui S. Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. J Immunol. 2008 Feb 01; 180(3):1948-53.
-
Dhanasekaran A, Al-Saghir R, Lopez B, Zhu D, Gutterman DD, Jacobs ER, Medhora M. Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature. Am J Physiol Heart Circ Physiol. 2006 Aug; 291(2):H517-31.